Home

Measuring what matters

The critical gap in multiple sclerosis disability impact

This programme was commissioned by Sanofi. Economist Enterprise conducted the research independently and retains full editorial control.

hero-imagehero-decor-tlhero-decor-trhero-decor-brhero-decor-bl
Supported byLogo Sanofi
Explore key findings

Multiple sclerosis (MS) is a lifelong disease that causes growing disability and significant challenges for patients, carers, and health systems. Every five minutes, someone is diagnosed, and three million people live with MS worldwide. MS frequently affects people at the height of their working and family-building years.

Our research captures this multifaceted burden of disability through economic modelling and a new survey of neurologists, assessing how MS is measured and managed across seven countries to expose gaps and spotlight best practices.

Together, the findings show a chain reaction. What is invisible is under-measured; what is under-measured is under-treated; and what is under-treated becomes a wider burden on lives, economies and healthcare systems.

Key findings

Tap to Explore

Measuring what matters

Bridging the gap between disability impact and economic burden in multiple sclerosis

Explore the survey results capturing neurologists’ views and experiences with measuring and managing MS-related disability, and our analysis of the economic impact of MS-related disability across France, Germany, Italy, Spain, Sweden, the UK and the US.

Download whitepaper